Clinical Trial Update: 124I-MIBG Tracer Evaluation of Myocardial Sympathetic Denervation and Assessment of Neuroendocrine Tumors. [Phase 2]

View source ↗

Summary

This entry describes a Phase 2 clinical trial evaluating 124I-MIBG tracer for assessing myocardial sympathetic denervation and imaging neuroendocrine tumors, co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor
• Parkinson Disease

Drugs mentioned

• 124I-MIBG tracer (metaiodobenzylguanidine (MIBG) labeled with iodine-124)

Snippet

Sponsor: Tel-Aviv Sourasky Medical Center | Conditions: Parkinson Disease, Neuroendocrine Tumors | Phase 2 | Status: UNKNOWN